GT Biopharma, Inc.
GTBP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000109657
No open-market purchases or sales by GT Biopharma, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $1.02M in total; no superinvestor holds it.
Holders of 5% or more of GTBP
Holders whose latest Schedule 13D or 13G filing reports 5% or more of GT Biopharma, Inc., largest stake first. The change is against the holder's previous filing.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
3 Schedule 13D and 13G filings on GT Biopharma, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Jun 2, 20257:46 PM ET | Bristol Investment Fund Ltdand 1 other | 13G/A | 4.76%0 shares | –Below 5% | May 29, 2025 | SEC |
| May 14, 20259:22 AM ET | Five Narrow Lane LP | 13G | 9.99%253.4K shares | New | May 13, 2025 | SEC |
| Oct 17, 202411:15 AM ET | Cytovance Biologics Inc | 13G/A | 9.80%219.5K shares | – | Sep 30, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell GT Biopharma, Inc. shares.
No Form 144 notices for GT Biopharma, Inc. are on file.